Physostigmine

Phase 3Small molecule

AstraZeneca

Physostigmine is one of 64 small molecule programs targeting Insulin resistance. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Insulin ResistanceActive, not recruiting

DeliriumActive, not recruiting

Insulin ResistancePhase 1

Active, not recruiting

DeliriumPhase 3

Active, not recruiting

Competition

Competitive Landscape

169 competitors in Insulin Resistance

#DrugCompanyPhaseTrials

Edarbi

Takeda

Phase 3

1 2

Jardiance

Boehringer Ingelheim

Phase 3

2 3

Januvia

ZZydus Therapeutics Inc.

Phase 3

2 4

Parlodel

VVeroScience

Phase 3

1 5

Glucophage

Boehringer Ingelheim

Phase 3

1 6

Deltavit

HHyundai Pharmaceutical Co., LTD.

Phase 3

1 7

Metformin Hcl

Boehringer Ingelheim

Phase 3

2 8

Avandia

GSK

Phase 3

1 9

Actos

Roche

Phase 2

1 10

Physostigmine

AstraZeneca

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Sedation2 trials

Phamacological Reversal of Airway Instability During Sedation

Completed·UUniversity of Rochester·N/A·NCT01171118·10 enrolled

The Effect of Physostigmine on Cognitive Functioning in the Immediate Period After Sedation for Colonoscopy

Unknown status·RRabin Medical Center·N/A·NCT01121497·160 enrolled

Tobacco Smoking1 trial

Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors

Completed·YYale University·N/A·NCT02008292·80 enrolled

Opioid Analgesia1 trial

Pilot Study of Physostigmine-Enhanced Opioid Analgesia

Completed·MMedical University of Graz·Phase 3·NCT01394445·20 enrolled

Adolescent1 trial

Treatment of Adolescent Antimuscarinic (Anticholinergic) Toxidrome

Completed·UUniversity of Colorado, Denver·Phase 4·NCT03090620·19 enrolled

Delirium1 trial

Evaluation if Physostigmine Reduces Symptoms in Patients Who Has Developed a Delirium in Intensive Care After a Surgery

Unknown status·PPD Dr. Bertram Scheller·Phase 3·NCT02216266·120 enrolled

3 more indications

General Anesthesia1 trial

Physostigmine After General Anesthesia

Unknown status·—·N/A·NCT00850850·50 enrolled

Insulin resistance1 trial

Pharmacological Intervention in Insulin Resistance Targeting Autonomic Nerve Activity

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT00689208·12 enrolled

Unspecified1 trial

Anticholium® Per Se

Completed·UUniversity Hospital Heidelberg·N/A·NCT03013322·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Physostigmine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Physostigmine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Physostigmine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AstraZeneca

Physostigmine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Sedation2 trials

Tobacco Smoking1 trial

Opioid Analgesia1 trial

Adolescent1 trial

Delirium1 trial

General Anesthesia1 trial

Insulin resistance1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News